A detailed history of Geneos Wealth Management Inc. transactions in Cassava Sciences Inc stock. As of the latest transaction made, Geneos Wealth Management Inc. holds 75 shares of SAVA stock, worth $206. This represents 0.0% of its overall portfolio holdings.

Number of Shares
75
Previous 75 -0.0%
Holding current value
$206
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 11, 2023

BUY
$16.64 - $25.32 $1,248 - $1,899
75 New
75 $1,000
Q1 2022

May 16, 2022

SELL
$32.6 - $53.05 $3,260 - $5,305
-100 Reduced 22.78%
339 $12,000
Q3 2021

Nov 09, 2021

BUY
$41.79 - $135.3 $8,149 - $26,383
195 Added 79.92%
439 $26,000
Q4 2020

May 19, 2021

BUY
$6.79 - $12.25 $679 - $1,225
100 Added 69.44%
244 $11,000
Q3 2020

Sep 07, 2021

BUY
$2.86 - $11.51 $411 - $1,657
144 New
144 $1,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $110M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Geneos Wealth Management Inc. Portfolio

Follow Geneos Wealth Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geneos Wealth Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Geneos Wealth Management Inc. with notifications on news.